Background
In the management of anesthesia during cardiac surgery, it is important to stably maintain the patient’s cardiovascular function throughout the operation. Therefore, it is necessary to carefully evaluate the patient’s cardiovascular function before surgery, monitor their general condition, and choose sedatives and analgesics carefully during anesthesia management. On the other hand, remimazolam, an ultra-short-acting benzodiazepine, has been available for use in Japan since 2020 [1]. This drug has a short half-life and causes minimal circulatory depression [2], making it a suitable sedative for patients with decreased cardiac function. In this report, we used remimazolam safely in the anesthesia management of coronary artery bypass graft (CABG) surgery, and present our findings. Written informed consent was obtained from the patient to publish this case report.